Effect of a new antirheumatic drug (CGS10787B) on antibody formation and delayed-type hypersensitivity in BALB/c mice.
The effect of CGS10787B on antibody formation and cell-mediated (delayed-type) hypersensitivity in BALB/c mice was examined by using the haemolytic plaque-forming cell assay and the delayed-type footpad reaction with the assay of T-cell subsets. CGS10787B at doses of 5, 25 and 100 mg/kg p.o. enhanced spleen haemolytic plaque-formation on day 4, and spleen rosette-formation on day 5 after immunization. In the assay of T-cell subsets, CGS10787B at the dose of 100 mg/kg reduced the Lyt-23 positive cell subset. In type III hypersensitivity, CGS10787B at doses of 5, 25 and 100 mg/kg p.o. for 6 days reduced dose-relatedly the footpad swelling of the immunized mouse. In type IV hypersensitivity, CGS10787B at doses of 5, 25 and 100 mg/kg p.o. for 6 days diminished dose-dependently the footpad swelling augmented by cyclophosphamide pretreatment. In the assay of T-cell subsets, CGS10787B at doses of 25 and 100 mg/kg increased the Thy-1 positive cell subset. These findings suggest that CGS10787B has an influence on the immune systems, acting on the function of T lymphocytes as well as on the inflammatory process in immunized animals.
Akita
S
S
Preclinical Research Department, Ciba-Geigy Japan Ltd., Takarazuka, Japan.
Abe
C
C
Hirose
S
S
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000917:Antibody Formation / Q000187:drug effects*; D003114:Colony-Forming Units Assay; D003520:Cyclophosphamide / Q000627:therapeutic use; D004008:Diclofenac / Q000627:therapeutic use; D005260:Female; D006968:Hypersensitivity, Delayed / Q000188:drug therapy*; D007978:Levamisole / Q000627:therapeutic use; D051379:Mice; D008807:Mice, Inbred BALB C; D011758:Pyrroles / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000276:immunology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D011758:Pyrroles; D004008:Diclofenac; D007978:Levamisole; C052921:prinomide; D003520:Cyclophosphamide